There's a link in the "news" section to a Seeking Alpha article. It's a good, simple comparison of ABT and ABBV, with ABBV coming out as the stronger of the two, at least in the short term. The yield on ABBV will be about 3X that of ABT, and because ABT carries a large amount of debt, it is unlikely to increase the dividend by much. On the other hand, ABBV is pretty much a one-product company, and it will be difficult to change that before patent expiration. Not in any hurry, but I think I'm leaning toward selling both. I had a nice career in the pharmaceutical industry, and I know how difficult it has become to bring blockbuster drugs to the market. The business model has changed greatly, and it will change drastically over the next decade.
Thanks for your thoughtful, in-depth response. Perhaps you could share just a little bit more of your reasoning. Is SA confused about the ABBV yield being 3X that of ABT? Or about the amount of debt the two are carrying? Or about ABBV being dependent on a single product for over 50% or its earnings? Just not sure what earned your verdict of "silly."